Synlogic (NASDAQ:SYBX) Shares Cross Below 50-Day Moving Average – What’s Next?

Synlogic, Inc. (NASDAQ:SYBX) shares passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.42 and traded as low as $1.41. Synlogic shares last traded at $1.50, with a volume of 28,219 shares trading hands.

Synlogic Stock Down 1.8 %

The firm’s 50 day simple moving average is $1.42 and its 200-day simple moving average is $1.47. The company has a market capitalization of $17.19 million, a PE ratio of -0.35 and a beta of 0.80.

Synlogic (NASDAQ:SYBX) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.17. Synlogic had a negative return on equity of 207.84% and a negative net margin of 2,284.65%. As a group, sell-side analysts anticipate that Synlogic, Inc. will post -2.71 EPS for the current fiscal year.

Synlogic Company Profile

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.